Full Press Release Details
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
ZBIO
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Key Takeaway: Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Price reaction · baseline $18.19 (2026-06-16 close) · hit after-hours · clean, no other ZBIO news in the window
day 0 close · peak
+2.1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+116%
120-day peak, hindsight
Typical move
8.9%
average across 3 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Orelabrutinib
Phase 3 · Multiple Sclerosis (MS) Primary Progressive